Additionally, medication acceptance rates of baseline adherers on follow up is currently unknown. Aims: 1) To investigate the effects and durability of IBD pharmacist targeted counselling intervention on adherence Selleckchem Lumacaftor rates, necessity and concerns with the primary outcome of increasing medication acceptance. 2) To test whether adherence at baseline changes on long term follow up. Methods: Patients were recruited from the IBD clinic of a Sydney tertiary hospital. Medication Adherence

Rating scale (MARS) questionnaire screened for non-adherence (defined as score ≤16). Beliefs about Medications Questionnaire (BMQ) addressed necessity and concerns (with “medication acceptance” defined as high Necessity >15/ low Concerns score ≤15). Non-adherers were targeted for a structured personalized counselling session with an IBD pharmacist addressing misperceptions, concerns, risk and other queries. Adherers (MARS ≥ 17) were recruited as controls. All patients were followed up with 3-monthly MARS and BMQ questionnaires. Data were analyzed using the Wilcoxon signed rank and Kruskal-Wallis non-parametric statistics and Chi square test. Results: A total of 89 consecutive patients (49% males, median age 37 years, 67% Crohn’s, PS-341 concentration median follow up 12 months, 48% 5-ASA, 66% immunomodulator, 26% biological agent) were prospectively recruited and 21 (23.5%) were non-adherers. For non-adherers, baseline median MARS was 16 increasing

to 19.0 at 3 months (P = 0.02) corresponding to significant increase in medication acceptance rate (P = 0.007). Medication acceptance rates at baseline for non-adherers and adherers were 10.5% and 44.3% respectively (P = 0.008) and at 3 months they were 58.3% and 42.3% respectively (P = 0.358, Table 1). Durability of acceptance was up to 15 months in non-adherers (66.6% P = 0.015) but had declined in baseline adherers

(23.0%, P = 0.095). Non-adherers’ Concern scores significantly decreased from baseline to 3 months (median difference 6, P = 0.033), MCE公司 9 months (median difference 6, P = 0.030) with a durable trend at 15 months (median difference 7, P = 0.08). Although baseline adherers’ median MARS increased from 19 to 20 at 15 months (P = 0.028), 9% had become non-adherent on follow up. Conclusion: Targeted pharmacist counselling intervention on non-adherers effectively increases medication acceptance rates to be equivalent to adherers and was durable to at least 15 months. Medication concerns decreased significantly and were sustained for at least 9 months for non-adherers. However, 9% of adherers became non-adherent at follow up with decreasing medication acceptance rates by 15 months. Medication adherence, therefore, is a dynamic factor that may change over time. Overall, a single targeted session is impactful not only by affecting concerns and adherence in the short term but by initiating a shift in the patient’s attitudes towards their medications. Table 1.